Physician profile
Christopher Diaz
NPI 1821594391
$2,595.91
in general payments reported to CMS, 2019-2025
10 companies · $770 in 2025
The $770 reported for 2025 was more than what 75% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $427 · 2024: $1,398 · 2025: $770.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,596.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,595.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $1,092.08 | 2023-2025 | Biktarvy |
| Viiv Healthcare Company | $936.90 | 2023-2025 | Dovato, Cabenuva, Rukobia |
| Merck Sharp & Dohme LLC | $289.58 | 2023-2025 | Pifeltro, Delstrigo, Dificid |
| Theratechnologies INC. | $84.76 | 2024-2025 | Egrifta, Trogarzo |
| Indivior INC. | $73.43 | 2023-2025 | Sublocade |
| Abbvie INC. | $37.21 | 2023-2024 | |
| Bausch Health US, LLC | $25.00 | 2023 | Aplenzin |
| Napo Pharmaceuticals INC | $24.44 | 2025 | Mytesi |
| Novartis Pharmaceuticals Corporation | $18.43 | 2024 | |
| Axsome Therapeutics, INC. | $14.08 | 2023 | Auvelity |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Diaz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.